Cambium Bio Limited (ASX:CMB)

• Co-founder of digital therapeutics company OME Health, London, UK.
• Co-founder of cell therapy CDMO SingCell, Singapore.
• Vice President, Healthcare Investment Banking, HSBC, London, UK.
• Finance Director, Danone Early Life & Clinical Nutrition, Baltic States.
• Regional Treasurer for Asia at the International Society for Cell and Gene Therapy (ISCT).
• MS in Biotechnology at Northeastern University, Boston, Massachusetts, USA.
• MBA at IESE Business School, Barcelona, Spain.
• Joined Cambium Bio in 2020.

• Co-founder of Cambium Medical Technologies in 2013.
• Professor of Medicine, Pathology & Hematology/Oncology at Emory University, Atlanta, GA.
• Vice President, Healthcare Investment Banking, HSBC, London, UK.
• Multiple other roles at Emory University, Atlanta, GA.
• PhD at The Rockefeller University, New York City, NY.
• MD at Cornell University Medical College, Ithaca, NY.
• BA at Harvard University, Cambridge, MA.

• Founder and Chairman of Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), a holding company for AventaCell, Dr. Wells, and other biomedical and healthcare businesses.
• Assistant Professor at Taipei Medical University.
• Chairman of the Asia Pacific Academy of Implant Surgery.
• Doctor of Dental Surgery at the College of Dentistry of New York University.
• Bachelor of Dental Surgery at College of Chung Shan Medical University.

• Co-founder of Cambium Medical Technologies in 2013.
• CEO of 3Ti (automated blood analyzer start-up).
• CEO of Refocus Group (ophthalmic device start-up).
• CMO of Autonomous Technologies (refractive surgery start-up).
• VP WW Sales, Marketing and BD at Novartis (CIBA Vision).
• MBA at The University of Notre Dame, Indiana.
• BS in Marketing at Indiana University, Indiana.

• 20+ years of experience as a director, business executive, and corporate lawyer.
• Executive Director of Sherman Group.

Clinical A/Prof Chandra Bala, MBBS, PhD, will join Cambium's Board effective 22November2024. A world-renowned ophthalmologist, A/Prof Bala brings extensive expertise in cataract, cornea, and refractive surgery. His distinguished career spans academia, research, and clinical practice, with numerous publications in international peer-reviewed journals and significant involvement in Phase 2 to 4 ophthalmic clinical trials. As senior partner at PersonalEyes, a leading ophthalmic group operating 12 clinics across Australia, and in his role as a cornea surgeon at Macquarie University Hospital, A/Prof Bala demonstrates a commitment to excellence in patient care. His dedication to advancing ophthalmic medicine through translational research, teaching, and community service aligns perfectly with Cambium's mission to innovate in the field of regenerative medicine.

Mr. Chiu is the Chairman of Hocheng Corporation (TWO:1810), a publicly-listed industrial company on the Taipei Stock Exchange with a market capitalization of approximately 5.2 billion TWD. He brings extensive corporate leadership experience to Cambium Bio, having led Hocheng Corporation since 2003. Following Cambium Bio's recent capital raising, Mr. Chiu holds 800,357 shares, representing a 4.38% stake in the Company.

Mr. Chiu brings over 35 years of corporate leadership experience across multiple industries. His career includes senior roles at Hostan Corporation (Vice President, 1998- 2003), Hocheng Corporation (Marketing Department Manager, 1996-1998), Sanquan Construction (Executive Director, 1993-1996), Hocheng Corporation North America Branch (Vice President, 1990-1993), and Hanyang Construction (Construction Site Director, 1988-1990). He holds a degree from the University of San Francisco, which he obtained in 1987.